[1] |
ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan.
Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
|
[2] |
LIU Saiyue, LYU Xiaoqin, ZHOU Yun.
Key points of investigation and report of suspected death of adverse drug reaction
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
|
[3] |
LI Xingren, SHEN Aizong, SU Dan.
Evaluation of the rationality of proton pump inhibitors in preventing perioperative stress related mucosal disease in biliary and pancreatic surgery
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1022-1026.
|
[4] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[5] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[6] |
DENG Yurong, SUN Jianhui, HAO Liyu, SHAN Zhongchao, YU Zeyue, LI Jianliang, HUO Hairu, LI Qijing, ZHANG Hongmeng, LI Hongmei.
Therapeutic effect and mechanism of Bairui granules against influenza virus-induced viral pneumonia in mice
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1249-1255.
|
[7] |
ZHUANG Hongyan, ZANG Yannan, LIU Shanshan, NIU Mengxi, FANG Meng, YIN Dongqing, GUO Wei.
Analysis of neuropsychiatric adverse reactions caused by zolpidem
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 889-892.
|
[8] |
XU Zhe, JU Ping, LUO Qi, YANG Huan, WANG Yang.
930 cases of adverse drug reactions induced by antibacterial drugs in children
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 317-321.
|
[9] |
ZHANG Yongheng, HAN Chen, YANG Xiao, HAN Xiuqi, YUAN Hongchang, DENG Zhijian.
Analysis of 313 Instructions for Injectable Drugs
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 669-673.
|
[10] |
XI Yuling, HUI Hongyan, GUO Xiaohe, DENG Zhijian.
Literature Analysis of Anaphylactic Shock Induced by Reduced Glutathione for Injection
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 674-677.
|
[11] |
LI Yaolei, ZHANG Bing, ZHANG Xiaomeng, LIN Zhijian.
Evaluation and Consideration of Clinical Safety of Traditional Chinese Medicine Based on Toxic Components
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 520-524.
|
[12] |
LI Sheng, ZHENG Lei.
Clinical Use and Safety of Oseltamivir Phosphate
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 250-255.
|
[13] |
CHEN Huanlei, LI Ning, ZHENG Xueling.
112 Cases of Hypersensitivity Induced by Methylprednisolone Sodium Succinate
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 155-159.
|
[14] |
ZHANG Jie, MAO Qiantai, AI Chao.
Evaluation of Potentially Inappropriate Medications in Elderly Outpatients
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1087-1090.
|
[15] |
BAI Shunmin, FAN Zhe.
Improper Prescriptions for Antitumor Drugs in Pharmacy Intravenous Admixture Services
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(4): 239-244.
|